Big pharma companies need to buy innovation, biotech companies are getting sky-high valuations, and 2018 is shaping up to be the second biggest M&A year for the sector on record.
Category: NYSE:NVS
Pharma R&D Investments Moderating, But Still High
However, it is clear that the pharmaceutical industry is going to continue to invest in R&D at a pretty healthy rate for the foreseeable future.
- 1
- 2
